Niki Karavitaki on the risk of brain tumours after radiotherapy for pituitary adenoma
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Niki Karavitaki on the risk of brain tumours after radiotherapy for pituitary adenoma
-
Narrated by:
-
By:
Summary
Niki Karavitaki talks with The Lancet Diabetes & Endocrinology about the risk of a second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma. Read the full article: Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma
Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
The Lancet Diabetes & Endocrinology in conversation with... is part of the Lancet Group podcast offering.
Editorial team: Marta Koch, David Holmes, and Susan Rahimi
Podcast editing and production: Matteo Simonetti
Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.
Find the best science for better lives at https://www.thelancet.com/journals/landia/home Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv